MY149545A - Topical single phase pharmaceutical formulation containing diclofenac, ketorolac or ketoprofen - Google Patents
Topical single phase pharmaceutical formulation containing diclofenac, ketorolac or ketoprofenInfo
- Publication number
- MY149545A MY149545A MYPI20093774A MYPI20093774A MY149545A MY 149545 A MY149545 A MY 149545A MY PI20093774 A MYPI20093774 A MY PI20093774A MY PI20093774 A MYPI20093774 A MY PI20093774A MY 149545 A MY149545 A MY 149545A
- Authority
- MY
- Malaysia
- Prior art keywords
- single phase
- ketorolac
- ketoprofen
- pharmaceutical formulation
- formulation containing
- Prior art date
Links
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001259 diclofenac Drugs 0.000 title abstract 2
- 230000000699 topical effect Effects 0.000 title abstract 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 title 1
- 229960000991 ketoprofen Drugs 0.000 title 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 title 1
- 229960004752 ketorolac Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 150000005846 sugar alcohols Polymers 0.000 abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0704846.5A GB0704846D0 (en) | 2007-03-13 | 2007-03-13 | Topical pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY149545A true MY149545A (en) | 2013-09-13 |
Family
ID=37988913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20093774A MY149545A (en) | 2007-03-13 | 2008-02-15 | Topical single phase pharmaceutical formulation containing diclofenac, ketorolac or ketoprofen |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8541470B2 (enExample) |
| EP (2) | EP2131813B1 (enExample) |
| JP (1) | JP2010521442A (enExample) |
| CN (1) | CN101663022A (enExample) |
| AU (1) | AU2008224735B2 (enExample) |
| BR (1) | BRPI0808887A2 (enExample) |
| CA (1) | CA2680074C (enExample) |
| CO (1) | CO6220926A2 (enExample) |
| DK (1) | DK2131813T3 (enExample) |
| ES (1) | ES2391914T3 (enExample) |
| GB (1) | GB0704846D0 (enExample) |
| MX (1) | MX2009009758A (enExample) |
| MY (1) | MY149545A (enExample) |
| NZ (1) | NZ579895A (enExample) |
| PL (1) | PL2131813T3 (enExample) |
| PT (1) | PT2131813E (enExample) |
| RU (1) | RU2468794C2 (enExample) |
| SG (1) | SG179480A1 (enExample) |
| TW (1) | TWI367110B (enExample) |
| UA (1) | UA100509C2 (enExample) |
| WO (1) | WO2008110741A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3300721T4 (da) * | 2003-11-20 | 2025-03-03 | Novo Nordisk As | Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger |
| JO3032B1 (ar) | 2008-10-17 | 2016-09-05 | Xenon Pharmaceuticals Inc | مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية. |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| KR20120099429A (ko) | 2009-10-14 | 2012-09-10 | 제논 파마슈티칼스 인크. | 스피로-옥스인돌 화합물의 합성 방법 |
| WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| HK1205114A1 (en) | 2012-04-12 | 2015-12-11 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| KR102235264B1 (ko) * | 2013-01-14 | 2021-04-02 | 인퍼스트 헬스케어 리미티드 | 고용체 조성물들 및 심각한 통증에서의 이들의 용도 |
| EP2943183A1 (en) * | 2013-01-14 | 2015-11-18 | InFirst Healthcare Limited | Compositions and methods for treating severe pain |
| CA2898017A1 (en) * | 2013-02-04 | 2014-08-07 | Infirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| US9012402B1 (en) | 2014-06-11 | 2015-04-21 | James Blanchard | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation |
| US10561627B2 (en) | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
| US11007161B1 (en) | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
| US10596117B1 (en) | 2014-12-31 | 2020-03-24 | Eric Morrison | Lipoleosomes as carriers for aromatic amide anesthetic compounds |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| GB201502845D0 (en) * | 2015-02-20 | 2015-04-08 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| FR3041534B1 (fr) * | 2015-09-30 | 2019-03-15 | Vetoquinol Sa | Composition de nettoyant auriculaire |
| GB201609968D0 (en) * | 2016-06-07 | 2016-07-20 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| US10100060B2 (en) | 2016-06-16 | 2018-10-16 | Xenon Pharmaceuticals Inc. | Asymmetric synthesis of funapide |
| CN110545796A (zh) * | 2017-03-07 | 2019-12-06 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 用于活性化合物的局部递送系统 |
| US10821075B1 (en) | 2017-07-12 | 2020-11-03 | James Blanchard | Compositions for topical application of a medicaments onto a mammalian body surface |
| KR102665710B1 (ko) | 2017-08-24 | 2024-05-14 | 노보 노르디스크 에이/에스 | Glp-1 조성물 및 그 용도 |
| JP7761567B2 (ja) | 2020-02-18 | 2025-10-28 | ノヴォ ノルディスク アー／エス | 医薬製剤 |
| GB2596286B (en) | 2020-06-20 | 2023-01-25 | Francis Davis Adrian | Adherence to topical therapy |
| WO2022023348A1 (en) | 2020-07-27 | 2022-02-03 | Incanthera (R&D) Ltd | Topical formulation |
| GB2597526A (en) | 2020-07-27 | 2022-02-02 | Incanthera R&D Ltd | Topical formulation |
| GB202012836D0 (en) | 2020-08-17 | 2020-09-30 | Futura Medical Developments Ltd | Topical composition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06104624B2 (ja) | 1986-05-07 | 1994-12-21 | 太郎 小木曽 | 経皮吸収剤 |
| PE20011092A1 (es) | 2000-02-14 | 2001-11-12 | Procter & Gamble | Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene reducida irritacion de la piel |
| DE10019171A1 (de) * | 2000-04-07 | 2001-10-18 | Schering Ag | Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe |
| AR041021A1 (es) * | 2002-08-22 | 2005-04-27 | Novartis Consumer Health Sa | Composicion topica |
| US7132452B2 (en) * | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
| WO2005027977A2 (en) * | 2003-09-22 | 2005-03-31 | Agis Industries (1983) Ltd. | Diclofenac compositions for the treatment of skin disorders |
| EP1588697A1 (en) | 2004-04-16 | 2005-10-26 | Kurt H. Prof. Dr. Bauer | Emulsion gel for topical application of pharmaceuticals |
| US20050244522A1 (en) | 2004-04-30 | 2005-11-03 | Carrara Dario Norberto R | Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents |
-
2007
- 2007-03-13 GB GBGB0704846.5A patent/GB0704846D0/en not_active Ceased
-
2008
- 2008-02-15 CA CA2680074A patent/CA2680074C/en active Active
- 2008-02-15 PT PT08709428T patent/PT2131813E/pt unknown
- 2008-02-15 CN CN200880007936A patent/CN101663022A/zh active Pending
- 2008-02-15 BR BRPI0808887-0A patent/BRPI0808887A2/pt not_active Application Discontinuation
- 2008-02-15 EP EP08709428A patent/EP2131813B1/en not_active Not-in-force
- 2008-02-15 ES ES08709428T patent/ES2391914T3/es active Active
- 2008-02-15 RU RU2009136228/15A patent/RU2468794C2/ru active
- 2008-02-15 WO PCT/GB2008/000540 patent/WO2008110741A2/en not_active Ceased
- 2008-02-15 EP EP12154983A patent/EP2452671A2/en not_active Withdrawn
- 2008-02-15 AU AU2008224735A patent/AU2008224735B2/en not_active Ceased
- 2008-02-15 US US12/530,960 patent/US8541470B2/en active Active
- 2008-02-15 DK DK08709428.0T patent/DK2131813T3/da active
- 2008-02-15 NZ NZ579895A patent/NZ579895A/en not_active IP Right Cessation
- 2008-02-15 JP JP2009553196A patent/JP2010521442A/ja active Pending
- 2008-02-15 SG SG2012017497A patent/SG179480A1/en unknown
- 2008-02-15 PL PL08709428T patent/PL2131813T3/pl unknown
- 2008-02-15 UA UAA200910111A patent/UA100509C2/ru unknown
- 2008-02-15 MX MX2009009758A patent/MX2009009758A/es active IP Right Grant
- 2008-02-15 MY MYPI20093774A patent/MY149545A/en unknown
- 2008-02-20 TW TW097105840A patent/TWI367110B/zh not_active IP Right Cessation
-
2009
- 2009-10-08 CO CO09111579A patent/CO6220926A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ579895A (en) | 2012-02-24 |
| WO2008110741A8 (en) | 2009-11-19 |
| ES2391914T3 (es) | 2012-12-03 |
| CA2680074A1 (en) | 2008-09-18 |
| RU2009136228A (ru) | 2011-04-20 |
| AU2008224735A1 (en) | 2008-09-18 |
| WO2008110741A2 (en) | 2008-09-18 |
| TW200836769A (en) | 2008-09-16 |
| CO6220926A2 (es) | 2010-11-19 |
| EP2131813B1 (en) | 2012-08-08 |
| MX2009009758A (es) | 2009-09-24 |
| UA100509C2 (ru) | 2013-01-10 |
| SG179480A1 (en) | 2012-04-27 |
| EP2452671A2 (en) | 2012-05-16 |
| PT2131813E (pt) | 2012-10-31 |
| PL2131813T3 (pl) | 2012-11-30 |
| WO2008110741A3 (en) | 2009-03-12 |
| JP2010521442A (ja) | 2010-06-24 |
| BRPI0808887A2 (pt) | 2014-09-02 |
| CN101663022A (zh) | 2010-03-03 |
| RU2468794C2 (ru) | 2012-12-10 |
| US8541470B2 (en) | 2013-09-24 |
| EP2131813A2 (en) | 2009-12-16 |
| TWI367110B (en) | 2012-07-01 |
| GB0704846D0 (en) | 2007-04-18 |
| US20100099767A1 (en) | 2010-04-22 |
| AU2008224735B2 (en) | 2013-04-18 |
| CA2680074C (en) | 2016-07-12 |
| DK2131813T3 (da) | 2012-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY149545A (en) | Topical single phase pharmaceutical formulation containing diclofenac, ketorolac or ketoprofen | |
| IL208759B (en) | History of 2-cyanooleanolic acid modulated at position 17 and their use as anti-inflammatory antioxidants | |
| CL2008003910A1 (es) | Formulacion liquida, estable, conteniendo anticuerpo que comprende arginina y metionina; procedimiento para inhibir la deamidacion de moleculas de un anticuerpo que comprende agregar arginina a la formulacion liquida. | |
| IL196169A0 (en) | Bile acid derivatives and pharmaceutical compositions containing the same | |
| GEP20135847B (en) | Boronate ester compounds and pharmaceutical compositions containing them | |
| WO2010146172A3 (en) | New synthetic route for the preparation of alpha-amino boronic esters | |
| PT2344198T (pt) | Preparações farmacêuticas à base de lípidos para aplicação tópica | |
| WO2007077562A3 (en) | Antiseptic compositions and methods of using same | |
| GB201009466D0 (en) | System to generate and set up an adverstising campaign based on the insertion of advertising messages within an exchange of messages, | |
| IL208612A (en) | A pharmaceutical composition containing natural testosterone and a lipid-based carrier | |
| AU308852S (en) | Camera stand | |
| IL211683A0 (en) | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them | |
| ZA201103669B (en) | Peptide derivatives and use thereof as carriers for molecules in the form of conjugates | |
| CL2008003284A1 (es) | Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras. | |
| SI2058317T1 (sl) | Derivat estra aminofosforjeve kisline in S1P receptorski modulator, ki ga vsebuje kot učinkovino | |
| MX2012013700A (es) | Composiciones aromatizantes y usos de las mismas. | |
| EP2417208A4 (en) | ANAEROBIC ADHESIVE AND SEALANT COMPOSITIONS IN FILM FORMULA, FILM PULLEY ASSEMBLIES WITH SUCH COMPOSITIONS IN FILM FORM AND PREPARED APPLICATIONS VERSIONS THEREOF | |
| WO2010055119A3 (en) | Pharmaceutical composition comprising pimobendan | |
| ES2634034T3 (es) | Composiciones nutricionales con copos de fruta que contienen ácido docosahexenoico | |
| BR112012004916A2 (pt) | composições sns-595 estáveis e métodos de preparação | |
| AU310934S (en) | Camera stand | |
| PL2164941T3 (pl) | Sposób formulacji zapachowych składników aktywnych, dla ich ochrony i wydłużenia czasu ich oddziaływania | |
| WO2011124570A3 (en) | Oral film formulation | |
| AU308854S (en) | Camera stand | |
| MX2007006908A (es) | Estabilizacion de esteres de glucocorticoides con acidos. |